Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over

2.1 Brexucabtagene autoleucel (Tecartus, Kite) is indicated for 'the treatment of adult patients 26 years of age and above with relapsed or refractory B cell precursor acute lymphoblastic leukaemia'.

2.2 The dosage schedule is available in the summary of product characteristics for brexucabtagene autoleucel.

2.3 The list price for single infusion is £316,118 (excluding VAT, MIMS [Monthly Index of Medical Specialities] online, accessed February 2023).

2.4 The company has a commercial arrangement. This makes brexucabtagene autoleucel available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.